Biomimetic nanoparticle technology for cardiovascular disease detection and treatment
Cardiovascular disease (CVD), which encompasses a number of conditions that can affect
the heart and blood vessels, presents a major challenge for modern-day healthcare. Nearly …
the heart and blood vessels, presents a major challenge for modern-day healthcare. Nearly …
A thrombin‐activated peptide‐templated nanozyme for remedying ischemic stroke via thrombolytic and neuroprotective actions
Ischemic stroke (IS) is one of the most common causes of disability and death. Thrombolysis
and neuroprotection are two current major therapeutic strategies to overcome ischemic and …
and neuroprotection are two current major therapeutic strategies to overcome ischemic and …
Tissue plasminogen activator-based nanothrombolysis for ischemic stroke
Introduction: Thrombolysis with intravenous tissue plasminogen activator (tPA) is the only
FDA approved treatment for patients with acute ischemic stroke, but its use is limited by …
FDA approved treatment for patients with acute ischemic stroke, but its use is limited by …
Low-intensity focused ultrasound-responsive phase-transitional nanoparticles for thrombolysis without vascular damage: a synergistic nonpharmaceutical strategy
Y Zhong, Y Zhang, J Xu, J Zhou, J Liu, M Ye, L Zhang… - ACS …, 2019 - ACS Publications
Multimodal molecular imaging has shown promise as a complementary approach to
thrombus detection. However, the simultaneous noninvasive detection and lysis of thrombi …
thrombus detection. However, the simultaneous noninvasive detection and lysis of thrombi …
Encapsulation of tissue plasminogen activator in pH-sensitive self-assembled antioxidant nanoparticles for ischemic stroke treatment–synergistic effect of thrombolysis …
The medical treatment for stroke has advanced greatly in recent years. Thrombolytic therapy
with tissue plasminogen activator (t-PA) is one of the mainstream treatments, but it still has …
with tissue plasminogen activator (t-PA) is one of the mainstream treatments, but it still has …
Synthesis and applications of Fe3O4/SiO2 core-shell materials
M Sonmez, M Georgescu… - Current …, 2015 - ingentaconnect.com
Multifunctional nanoparticles based on magnetite/silica core-shell, consisting of iron oxides
coated with silica matrix doped with fluorescent components such as organic dyes …
coated with silica matrix doped with fluorescent components such as organic dyes …
Preclinical evaluation and clinical translation of magnetite-based nanomedicines
JV Nuzhina, AA Shtil, AY Prilepskii… - Journal of Drug Delivery …, 2019 - Elsevier
Over the last decade, magnetic iron oxide nanoparticles have attracted considerable interest
in the field of nanomedicine due to their unique magnetic properties, biocompatibility, and …
in the field of nanomedicine due to their unique magnetic properties, biocompatibility, and …
The promising shadow of microbubble over medical sciences: from fighting wide scope of prevalence disease to cancer eradication
Abstract Microbubbles are typically 0.5–10 μm in size. Their size tends to make it easier for
medication delivery mechanisms to navigate the body by allowing them to be swallowed …
medication delivery mechanisms to navigate the body by allowing them to be swallowed …
[HTML][HTML] Particles in coronary circulation: A review on modelling for drug carrier design
Atherosclerotic plaques and thrombosis are chronic inflammatory complications and the
main manifestations of cardiovascular diseases (CVD), the leading cause of death globally …
main manifestations of cardiovascular diseases (CVD), the leading cause of death globally …
Multimodal and multifunctional nanoparticles with platelet targeting ability and phase transition efficiency for the molecular imaging and thrombolysis of coronary …
S Bai, J Liao, B Zhang, M Zhao, B You, P Li… - Biomaterials …, 2020 - pubs.rsc.org
Recently, coronary microthrombosis has received attention owing to its involvement in the
pathophysiological process of no-reflow after acute myocardial ischemia/reperfusion. Due to …
pathophysiological process of no-reflow after acute myocardial ischemia/reperfusion. Due to …